GCC 0820 - Bone Marker-Directed Dosing of Zometa (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma
GCC 0823 - Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects with Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function.
GCC 0839 - Phase 1/2 Open-Label Study of the Safety and Efficacy of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Refractory Multiple Myeloma
GCC 0908 - An Open-Label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies
Email this Page
Print this Page
